Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.9
(-0.45%)
CNY 8.9
(-0.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1 Billion CNY | -31.71% |
| 2022 | 1.47 Billion CNY | 216.56% |
| 2021 | 465.67 Million CNY | 107.77% |
| 2020 | 224.13 Million CNY | 20.57% |
| 2019 | 185.89 Million CNY | -29.09% |
| 2018 | 262.14 Million CNY | 16.17% |
| 2017 | 225.65 Million CNY | -31.46% |
| 2016 | 329.24 Million CNY | 26.39% |
| 2015 | 260.5 Million CNY | -0.62% |
| 2014 | 262.13 Million CNY | 32.03% |
| 2013 | 198.54 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 756.36 Million CNY | -8.83% |
| 2024 Q2 | 829.61 Million CNY | -9.53% |
| 2024 Q1 | 917.04 Million CNY | -8.91% |
| 2023 Q1 | 1.17 Billion CNY | -20.47% |
| 2023 FY | 1 Billion CNY | -31.71% |
| 2023 Q4 | 1 Billion CNY | 7.09% |
| 2023 Q3 | 940.06 Million CNY | -13.67% |
| 2023 Q2 | 1.08 Billion CNY | -7.12% |
| 2022 FY | 1.47 Billion CNY | 216.56% |
| 2022 Q3 | 1.28 Billion CNY | 22.08% |
| 2022 Q2 | 1.05 Billion CNY | 75.82% |
| 2022 Q4 | 1.47 Billion CNY | 14.29% |
| 2022 Q1 | 600.94 Million CNY | 29.05% |
| 2021 Q1 | 293.3 Million CNY | 30.86% |
| 2021 Q3 | 367.42 Million CNY | 14.22% |
| 2021 Q4 | 465.67 Million CNY | 26.74% |
| 2021 FY | 465.67 Million CNY | 107.77% |
| 2021 Q2 | 321.68 Million CNY | 9.67% |
| 2020 Q4 | 224.13 Million CNY | 12.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 224.13 Million CNY | 20.57% |
| 2020 Q2 | 161.31 Million CNY | 0.0% |
| 2020 Q3 | 200.11 Million CNY | 24.05% |
| 2019 FY | 185.89 Million CNY | -29.09% |
| 2019 Q4 | 185.89 Million CNY | 0.0% |
| 2018 FY | 262.14 Million CNY | 16.17% |
| 2017 Q1 | 244.83 Million CNY | -25.64% |
| 2017 Q2 | 244.83 Million CNY | 0.0% |
| 2017 FY | 225.65 Million CNY | -31.46% |
| 2016 Q1 | 235.96 Million CNY | -9.42% |
| 2016 Q2 | 235.96 Million CNY | 0.0% |
| 2016 FY | 329.24 Million CNY | 26.39% |
| 2016 Q3 | 329.24 Million CNY | 39.53% |
| 2016 Q4 | 329.24 Million CNY | 0.0% |
| 2015 Q4 | 260.5 Million CNY | 0.0% |
| 2015 Q3 | 260.5 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | 260.5 Million CNY | -0.62% |
| 2014 FY | 262.13 Million CNY | 32.03% |
| 2013 FY | 198.54 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 87.454% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 80.749% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | 20.269% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | 30.773% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -30.301% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 33.234% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | 12.998% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -63.628% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 72.106% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -355.428% |